____________________________________________________________

TRENBOLONE COMPLETE COMPOUND GUIDE

all esters | mechanism | pharmacology | side effects | risk profile

____________________________________________________________

this thread covers what peer-reviewed literature and documented case reports

actually say about trenbolone. not a promotion. not a how-to guide.

cited sources throughout. harm reduction framing.

[1] Bauer ER et al. (2000) APMIS. AR binding affinity of trenbolone vs testosterone and DHT

[2] Yarrow JF et al. (2010) Steroids. Tissue selectivity and potential clinical applications of trenbolone

[3] Piatkowski TM et al. (2023) Drug Alcohol Rev. Qualitative exploration of trenbolone in PIED community

[4] Piatkowski TM et al. (2024) Int J Drug Policy. Trenbolone, psychological distress, and aggression

[5] Zelleroth S et al. (2019) Neurotoxicology. Trenbolone neurotoxicity in brain cell cultures

[6] World J Pharm Sci (2025). Adverse effects of trenbolone: structured review of 23 case reports

[7] Aknouche L et al. (2021) Forensic Sci Int. Trenbolone and cardiovascular complications

[8] Lise A et al. (2020) J Mol Struct. Structural studies of trenbolone and its ester forms

[9] Hickson RC et al. (1990) Med Sci Sports Exerc. Glucocorticoid receptor antagonism by anabolic steroids

[10] Toth M, Zakar T. (1982) J Steroid Biochem. AR binding affinity of trenbolone

____________________________________________________________

CONTENTS

01 what trenbolone is origin and legal status

02 the base molecule structure and what makes it different

03 mechanism of action androgen receptor IGF-1 glucocorticoid antagonism

04 trenbolone acetate TBA the short ester

05 trenbolone enanthate TE the long ester

06 trenbolone hexahydrobenzylcarbonate parabolan the human-approved ester

07 trenbolone base unesterified rare and rapid

08 ester comparison table half-life injection frequency peak and trough

09 what trenbolone actually does to body composition

10 HPTA suppression how complete and how fast

11 cardiovascular effects the evidence from case reports and studies

12 neurological and psychiatric effects the data

13 androgenic effects hair skin prostate why finasteride does not work

14 progestogenic activity gynecomastia without estrogen

15 hepatotoxicity

16 the complete side effect profile by system

17 detection times by ester

18 verdict risk summary

____________________________________________________________

01 WHAT TRENBOLONE IS ORIGIN AND LEGAL STATUS

Trenbolone is a synthetic anabolic-androgenic steroid (AAS) derived from

nandrolone. It belongs to the 19-nor testosterone family, meaning it lacks

the carbon atom at the 19 position of the steroid backbone.

Originally synthesised in the 1960s. Never approved by FDA for human use

in any ester form except trenbolone hexahydrobenzylcarbonate (Parabolan),

which had brief clinical use in France in the 1980s before withdrawal.

Current approved uses: veterinary only. Trenbolone acetate is the active

component of Finaplix-H and Revalor implants used in cattle to increase

lean mass and feed efficiency before slaughter.

____________________________________________________________

LEGAL STATUS

United States Schedule III controlled substance (Anabolic Steroid Control Act)

United Kingdom Class C controlled drug

Australia Schedule 4 prescription-only / Schedule 9 prohibited

Canada Schedule IV controlled substance

Most of EU prescription controlled or outright prohibited

WADA prohibited in all sports in and out of competition

No human-approved formulation exists anywhere in the world as of 2024.

All human-use trenbolone is sourced from underground laboratories.

Pharmaceutical-grade trenbolone for humans has not been commercially

produced since Parabolan was discontinued.

____________________________________________________________

02 THE BASE MOLECULE STRUCTURE AND WHAT MAKES IT DIFFERENT

IUPAC name: 17beta-hydroxyestra-4,9,11-trien-3-one

Molecular formula: C18H22O2 (free base)

Molecular weight: 270.37 g/mol (free base)

Three structural features separate trenbolone from testosterone and

from most other AAS. Each one has direct pharmacological consequences.

____________________________________________________________

FEATURE 1 THE DELTA-9,11 DOUBLE BOND (the triene system)

Trenbolone has three conjugated double bonds: at C4-C5, C9-C10, and C11-C12.

This triene system creates a rigid planar ring structure that dramatically

increases androgen receptor binding affinity.

The C9-C11 double bond makes trenbolone a poor substrate for aromatase.

Aromatase cannot process the delta-9,11 triene configuration.

Result: trenbolone does not convert to estrogen at any dose.

This is absolute. It is structural, not dose-dependent.

FEATURE 2 THE 19-NOR MODIFICATION

Like nandrolone, trenbolone lacks the C19 methyl group present in testosterone.

This modification reduces 5-alpha reductase activity.

5AR converts testosterone to DHT (more potent androgen in scalp and prostate).

With trenbolone: 5AR does not produce a more potent metabolite.

The parent compound is already maximally potent at the AR.

Consequence: finasteride and dutasteride offer zero protection against

trenbolone androgenic effects. They block 5AR. 5AR is not in the pathway.

FEATURE 3 THE 17-BETA HYDROXYL GROUP

The 17-beta hydroxyl is where ester chains are attached to produce the

injectable forms (acetate, enanthate, hexahydrobenzylcarbonate).

The ester acts as a depot: it is cleaved by esterases in tissue,

releasing free trenbolone gradually. Ester length determines release speed.

____________________________________________________________

03 MECHANISM OF ACTION

Trenbolone exerts its effects through at least three distinct mechanisms.

Understanding all three is necessary to understand both the efficacy

and the risk profile.

____________________________________________________________

MECHANISM 1 ANDROGEN RECEPTOR AGONISM

Trenbolone binds the androgen receptor with approximately 3x the affinity

of testosterone (Bauer et al. 2000; Toth and Zakar 1982).

The affinity is comparable to dihydrotestosterone (DHT).

This is confirmed in [3H]DHT displacement assays using the recombinant

human androgen receptor.

Once bound, the trenbolone-AR complex translocates to the nucleus and

activates transcription of androgen-responsive genes including:

nitrogen retention genes increased nitrogen balance in muscle

muscle protein synthesis genes upregulation of contractile protein production

IGF-1 gene expression local intramuscular IGF-1 production elevated

satellite cell activation muscle stem cell recruitment to myofibers

SHBG reduction lower sex hormone binding globulin systemically

The anabolic:androgenic ratio assigned to trenbolone is 500:500

vs testosterone at 100:100. These ratios are derived from rat levator ani

assays and do not translate directly to humans, but the directional

relationship is meaningful: trenbolone is approximately 5x more potent

than testosterone on a mg-per-mg basis by this measure.

____________________________________________________________

MECHANISM 2 GLUCOCORTICOID RECEPTOR ANTAGONISM

Trenbolone has documented binding activity at the glucocorticoid receptor

(Hickson et al. 1990). Glucocorticoids (primarily cortisol) are the primary

catabolic hormones. They drive muscle protein breakdown, reduce protein

synthesis, and promote fat storage.

Trenbolone competing at the glucocorticoid receptor suppresses this

catabolic signalling. The consequence is not just more anabolism but

less catabolism running simultaneously.

This dual effect (anabolic activation + catabolic suppression) is the

structural basis for the nutrient partitioning effect that distinguishes

trenbolone from most other AAS. Fat and muscle are affected simultaneously.

____________________________________________________________

MECHANISM 3 IGF-1 UPREGULATION

AR activation in muscle tissue directly upregulates local IGF-1 production

(Yarrow et al. 2010). IGF-1 in turn activates the PI3K/Akt/mTOR pathway,

which is the primary intracellular driver of muscle protein synthesis.

This creates a secondary amplification of the anabolic signal beyond the

direct AR genomic effect.

IGF-1 also activates satellite cells (muscle stem cells) which fuse with

existing myofibers, adding new myonuclei and expanding the muscle's

capacity for protein accretion. This satellite cell effect is part of why

gains from AAS cycles can persist beyond the cycle itself.

____________________________________________________________

04 TRENBOLONE ACETATE TBA THE SHORT ESTER

Chemical name: trenbolone 17beta-acetate

Molecular formula: C20H24O3

Molecular weight: 312.40 g/mol

CAS number: 10161-34-9

Trade names: Finajet, Finaject (historical human), Finaplix (veterinary)

Approved use: veterinary only (cattle growth promotion)

____________________________________________________________

PHARMACOKINETICS

Half-life after IM injection approximately 1-2 days

Active hormone window approximately 3 days per injection

Time to peak plasma levels approximately 24 hours post injection

Injection frequency required every other day (EOD) or daily for stable levels

Typical injection volume small (high concentration possible in short volume)

CHARACTERISTICS

The shortest and fastest ester. Peak plasma levels occur within 24 hours

of injection. Clears the system faster than any other trenbolone ester.

Faster clearance means side effects dissipate faster when the compound

is stopped. If a serious adverse event occurs, the drug clears quickly.

This is the primary clinical argument for acetate in a risk context.

Faster clearance also means more injection frequency. EOD injections

are required to maintain stable blood levels. Daily injections preferred

by some users for maximally stable plasma concentration curves.

The classic "tren cough" (sudden severe coughing fit immediately after

injection) is most commonly reported with acetate, though it can occur

with any ester. Mechanism is not fully established. Leading hypothesis:

micro-embolism of oil into a small vessel triggering prostaglandin-mediated

bronchospasm. Typically resolves within 60-90 seconds.

DETECTION TIME

Metabolite detection in urine: approximately 5 months (WADA testing)

____________________________________________________________

05 TRENBOLONE ENANTHATE TE THE LONG ESTER

Chemical name: trenbolone 17beta-enanthate

Molecular formula: C25H34O3

Molecular weight: 382.53 g/mol

CAS number: 10161-33-8

Trade names: no approved brand name. underground laboratory product only.

Approved use: none. never had human or veterinary approval.

____________________________________________________________

PHARMACOKINETICS

Half-life after IM injection approximately 7-10 days

Active hormone window approximately 14 days per injection

Time to peak plasma levels approximately 3-5 days post injection

Injection frequency required twice per week or once weekly

CHARACTERISTICS

Enanthate is the longest commercially available trenbolone ester.

Never had pharmaceutical approval. Exists only as an underground product.

Slower onset means blood levels build more gradually. Peak androgenic

and anabolic effects are delayed relative to acetate.

Twice-weekly injections maintain reasonably stable levels.

Some users inject once weekly accepting some peak-trough variability.

If side effects develop, longer time to clearance means longer duration

of exposure before the compound is gone. This is the primary risk difference

vs acetate. An adverse event on enanthate means days more exposure before

plasma levels fall meaningfully.

Lower injection frequency is the practical appeal. Many users find EOD

acetate injections inconvenient. Enanthate at twice weekly is simpler.

DETECTION TIME

Metabolite detection in urine: approximately 5-6 months (WADA testing)

____________________________________________________________

06 TRENBOLONE HEXAHYDROBENZYLCARBONATE PARABOLAN

Chemical name: trenbolone cyclohexylmethylcarbonate

Molecular formula: C26H34O4

Molecular weight: 410.55 g/mol

CAS number: 23454-33-3

Trade names: Parabolan (Negma Laboratories, France)

Approval history: approved for human use in France 1980. discontinued 1997.

Approved use: was approved for muscle wasting and osteoporosis. withdrawn.

____________________________________________________________

PHARMACOKINETICS

Half-life after IM injection approximately 8-14 days (sources vary: 8 per Lise 2020)

Active hormone window approximately 14-21 days per injection

Time to peak plasma levels approximately 3-7 days post injection

Injection frequency required once per week or once every 10 days

Historical clinical dose: 228 mg per 3 weeks (Parabolan ampule was 76 mg/1.5mL)

THE ONLY HUMAN-APPROVED TRENBOLONE HISTORICAL CONTEXT

Parabolan was the only trenbolone preparation ever approved for human use.

Negma Laboratories in France manufactured it for use in cachexia,

muscle wasting diseases, and osteoporosis.

It was withdrawn in 1997. Negma cited difficulty maintaining production

standards. The discontinuation is also attributed to the increasing

awareness of AAS misuse concerns and regulatory pressure.

No pharmaceutical-grade Parabolan has been manufactured for human use since 1997.

All products currently sold as Parabolan are underground laboratory products.

CHARACTERISTICS

The hexahydrobenzylcarbonate ester is a cyclic carbonate ester, structurally

different from the linear esters (acetate, enanthate). The cyclohexylmethyl

group provides a release profile intermediate between acetate and enanthate.

Half-life of approximately 8 days per Lise et al. 2020 crystal structure analysis.

Because Parabolan is the only human-approved form, some users treat it as

pharmacologically distinct. It is not. The ester is cleaved to yield the same

free trenbolone base as any other ester. Identical active molecule.

The only real difference is release kinetics.

DETECTION TIME

Metabolite detection in urine: approximately 5 months (WADA testing)

____________________________________________________________

07 TRENBOLONE BASE UNESTERIFIED

Chemical name: 17beta-hydroxyestra-4,9,11-trien-3-one

Molecular formula: C18H22O2

Molecular weight: 270.37 g/mol

Trade names: none. underground product.

Approved use: none anywhere.

____________________________________________________________

PHARMACOKINETICS

Half-life after IM injection approximately 6-8 hours

Active hormone window approximately 12-24 hours per injection

Time to peak plasma levels approximately 1-2 hours post injection

Injection frequency required daily or multiple times daily

CHARACTERISTICS

Trenbolone base (also called "tren base" or "aqueous tren") is the

unesterified free hormone. Without an ester chain, it enters the bloodstream

almost immediately after injection.

Used primarily as a pre-workout injection (pre-workout compound or PWO).

The acute AR spike produces rapid increases in aggression, drive,

and vascular blood flow immediately before training.

Extremely short half-life means rapid clearance. Also means injection pain

and local irritation is maximally intense due to high concentration and

rapid uptake. Injection site pain is a consistent report.

Daily or multiple daily injections required make this impractical for

sustained anabolic use. Used almost exclusively for acute pre-workout

effect rather than as a primary compound.

Rapid clearance means if adverse effects occur, levels drop fast.

Rapid onset also means any injection complication (embolism, abscess)

occurs with maximum speed and intensity.

____________________________________________________________

08 ESTER COMPARISON TABLE

Feature Acetate Enanthate Hexahydrobenzyl Base

____________________________________________________________

Half-life 1-2 days 7-10 days 8-14 days 6-8 hours

Active window 3 days 14 days 14-21 days 12-24 hours

Time to peak 24 hours 3-5 days 3-7 days 1-2 hours

Inject frequency EOD / daily twice weekly once weekly daily / PWO

Human approval never never France 1980-1997 never

Available as pharma no no no (since 1997) no

Clearance on stop fast (3 days) slow (2+ weeks) slow (2+ weeks) very fast

Detection (WADA) ~5 months ~5-6 months ~5 months shorter

Tren cough risk highest lower lower moderate

Molecular weight 312.40 382.53 410.55 270.37

All esters cleave to the same free trenbolone base in tissue.

Pharmacological effects are identical once the ester is removed.

The only variable is delivery speed and plasma concentration curve shape.

____________________________________________________________

09 WHAT TRENBOLONE ACTUALLY DOES TO BODY COMPOSITION

From veterinary data (Revalor implants in cattle) and human case series:

LEAN MASS ACCRETION

Animal data: Revalor implants producing sustained trenbolone release

in cattle increase lean mass by 20-30% compared to non-implanted controls.

This is the basis for FDA approval in veterinary use.

Yarrow et al. 2010 (Steroids): trenbolone increases LABC muscle mass by

35-40% in rodent models. Muscle protein deposition elevated. Protein

degradation reduced. Net positive protein balance.

In human users: nitrogen retention increases within days of initiating use.

Strength increases reported within 2-3 weeks. Visible body composition

changes within 4-6 weeks depending on dose and baseline.

FAT LOSS AND NUTRIENT PARTITIONING

The glucocorticoid receptor antagonism mechanism drives concurrent fat loss

alongside lean mass gain. Cortisol-driven fat storage is reduced.

Combined with AR-driven metabolic rate elevation and IGF-1 lipolytic signalling,

simultaneous fat loss and muscle gain is well-documented in animal data.

This body recomposition effect is what distinguishes trenbolone from

compounds like testosterone, which produce more water retention

and less concurrent fat loss.

NO WATER RETENTION

No aromatization = no estrogen = no estrogenic water retention.

Gains are predominantly contractile tissue. The characteristic

"hard, dry, vascular" appearance results from this.

____________________________________________________________

10 HPTA SUPPRESSION HOW COMPLETE AND HOW FAST

Trenbolone suppresses the hypothalamic-pituitary-testicular axis (HPTA)

rapidly and completely, even at low doses.

Mechanism: elevated exogenous androgen signals to the hypothalamus to

reduce GnRH pulse frequency. Lower GnRH means lower LH and FSH from

the pituitary. Without LH, Leydig cells in the testes cease producing

testosterone. Without FSH, spermatogenesis is impaired.

Disruptions of LH, FSH, testosterone, DHT, and estradiol have been

documented in multiple species following trenbolone exposure.

Indirect evidence in livestock: reduced testicular circumference and

delayed puberty in exposed animals.

____________________________________________________________

IN HUMAN USERS

Endogenous testosterone drops to near-zero within weeks on trenbolone alone.

LH and FSH crash. Without exogenous testosterone supplementation,

users experience hypogonadism symptoms during the cycle:

libido collapse, erectile dysfunction, depression, low energy.

After the cycle ends, HPTA recovery depends on:

duration of suppression / ester used / dose / individual recovery rate

PCT protocol (clomiphene, tamoxifen, hCG) can accelerate recovery.

Some users report prolonged HPTA suppression for months post-cycle.

Permanent HPTA suppression (hypogonadism requiring TRT) is documented

in long-term heavy AAS users in case reports.

____________________________________________________________

11 CARDIOVASCULAR EFFECTS THE EVIDENCE

The 2025 structured review of 23 case reports (World J Pharm Sci) found

cardiovascular complications were the most common serious adverse event

category in documented trenbolone cases.

____________________________________________________________

DOCUMENTED CARDIOVASCULAR ADVERSE EVENTS FROM CASE REPORTS

left ventricular hypertrophy (LVH) enlarged heart from pressure and volume overload

dilated cardiomyopathy weakened, enlarged cardiac chambers

myocardial infarction heart attack in young users without traditional RF

ischemic stroke documented in multiple case reports

advanced ischemic heart disease accelerated atherosclerosis

heart failure both systolic and diastolic dysfunction reported

coronary artery stenosis significant narrowing documented on angiography

pulmonary edema secondary to cardiac failure

MECHANISMS DRIVING CARDIOVASCULAR HARM

LDL elevation androgenic activity shifts hepatic lipid metabolism toward

increased LDL production and reduced HDL clearance.

LDL builds up in arterial walls. Atherosclerosis accelerates.

HDL suppression HDL can fall by 30-50% on AAS. HDL is the primary reverse

cholesterol transport mechanism. Removing it accelerates plaque.

Blood pressure elevated haematocrit (polycythaemia from androgen-driven

EPO stimulation) increases blood viscosity and BP.

Direct endothelial damage from androgen receptor activation.

LVH the heart muscle hypertrophies in response to elevated

afterload (high BP) and direct AR stimulation on cardiomyocytes.

Pathological LVH reduces diastolic filling and increases

arrhythmia risk.

Endothelial damage direct oxidative stress and endothelial dysfunction

accelerate fatty plaque formation and arterial stiffness.

Trenbolone is associated with cardiovascular complications (Aknouche et al. 2021).

The 2024 Int J Drug Policy review confirmed cardiovascular risk as a primary

documented harm in AAS users with trenbolone exposure.

____________________________________________________________

12 NEUROLOGICAL AND PSYCHIATRIC EFFECTS

Zelleroth et al. 2019 (Neurotoxicology): trenbolone exposure in brain cell

cultures caused significant cell damage and cell death. Toxicity was reduced

when cells were treated with an androgen receptor blocker, indicating the

harm is AR-mediated, not an off-target toxic effect.

____________________________________________________________

PSYCHIATRIC EFFECTS FROM PUBLISHED RESEARCH

aggression and irritability documented across multiple qualitative studies

(Piatkowski et al. 2023, 2024)

insomnia ("trensomnia") sleep disruption is one of the most consistently

reported effects in user surveys and case studies

impulsivity reduced behavioural inhibition documented

violent behaviour extreme violence including homicide documented

in case reports (2025 structured review)

acute psychosis documented in case reports

delirium documented in case reports

Wernicke's encephalopathy documented in one case report

relationship and social harm Piatkowski 2023: qualitative reports of relationship

breakdown and social withdrawal

THE SEROTONIN MECHANISM

19-Nor AAS as a class (nandrolone group) alter serotonin receptor density

in animals (Piatkowski et al. 2023 citing prior animal research).

Upregulation of serotonin receptors mimics the pattern seen in depressive

pseudodementia states. Reduced serotonin neurotransmission is believed

to underlie mood instability, aggression, and depressive symptoms.

Trenbolone's psychiatric effects are not simply placebo or expectation.

The serotonergic mechanism provides a plausible neurochemical basis.

NIGHT SWEATS

Extremely common and consistent user report. Mechanism not fully established.

Hypothesised: hypothalamic thermoregulation disruption via androgen receptor

activation in the preoptic area. Also possibly related to cortisol disruption

and altered autonomic thermoregulatory response. Considered a class-specific

effect of trenbolone rather than a general AAS effect.

____________________________________________________________

13 ANDROGENIC EFFECTS HAIR SKIN PROSTATE WHY FINASTERIDE FAILS

THE 5-ALPHA REDUCTASE PROBLEM

With testosterone: 5AR converts testosterone to DHT in scalp and prostate.

DHT is the androgen driving follicle miniaturisation and prostate growth.

Finasteride and dutasteride block 5AR, reducing DHT by 70-90%.

This is why they work for testosterone-induced hair loss.

With trenbolone: trenbolone does not undergo significant 5AR conversion.

The parent compound is already a more potent androgen than DHT at the AR.

Blocking 5AR does not reduce the androgenic signal from trenbolone.

There is no less-potent metabolite being converted to a more-potent one.

Finasteride and dutasteride are pharmacologically irrelevant to trenbolone.

The only mechanistically valid hair protection during trenbolone use:

direct AR antagonists at the scalp (topical RU58841, pyrilutamide, CB-03-01)

that compete with trenbolone for the scalp AR directly.

These are investigational compounds. Not approved. Evidence in this context

is anecdotal and user-reported, not from clinical trials.

____________________________________________________________

DOCUMENTED ANDROGENIC EFFECTS

male pattern baldness acceleration documented extensively in user population

in users with genetic predisposition

severe acne fulminant acne including cystic acne on

face, back, chest documented in case reports

body and facial hair growth virilisation in both males and females

prostate hypertrophy AR stimulation in prostate tissue

increased prostate cancer risk flagged in

2024 ScienceDirect review

virilisation in women clitoral enlargement, voice deepening,

irregular menstruation at low doses

irreversible changes documented

____________________________________________________________

14 PROGESTOGENIC ACTIVITY GYNECOMASTIA WITHOUT ESTROGEN

Trenbolone does not aromatize. It cannot directly raise estrogen.

Despite this, gynecomastia (breast tissue development) is documented

in trenbolone users. The mechanism is progestogenic activity.

Bauer et al. 2000 confirmed: 17beta-trenbolone binds the bovine progesterone

receptor with slightly higher affinity than progesterone itself.

Progestins sensitize breast tissue to estrogen. Even low baseline estrogen

levels (which remain present in all men) can drive gynecomastia when

progesterone receptor sensitivity is elevated.

Additionally, if trenbolone is stacked with aromatizing compounds

(testosterone, dianabol), elevated estrogen from those compounds combines

with trenbolone's progestogenic activity to increase gynecomastia risk

substantially beyond either compound alone.

Aromatase inhibitors address the estrogen component in stacked cycles.

Prolactin elevation from progestogenic activity responds to cabergoline.

These are management strategies for a known complication, not prevention.

____________________________________________________________

15 HEPATOTOXICITY

Trenbolone is an injectable compound, not 17-alpha alkylated.

17-AA modification is the primary driver of severe hepatotoxicity in oral AAS.

Injectable trenbolone does not carry the same hepatotoxic burden as orals.

However: hepatotoxicity IS documented in trenbolone case reports.

Cholestatic liver injury documented in case reports of trenbolone users

Hepatitis documented in case reports

Elevated liver enzymes (ALT, AST) consistently observed in clinical cases

Hepatic vascular lesions long-term AAS use including trenbolone associated

with peliosis hepatis in literature

One published case: 23-year-old male, 1000 mg/week trenbolone for 2 months.

Developed jaundice. Liver enzyme elevation on blood panel.

Characterised as AAS-associated hepatotoxicity (Am J Gastroenterology).

The 2025 structured review (23 cases) listed hepatic complications as a

primary adverse event category alongside cardiovascular and psychiatric harm.

Mechanism for injectable AAS hepatotoxicity: hepatic lipid processing burden,

bile acid secretion alteration, and direct androgenic effects on hepatocytes.

The bile acid nephropathy pathway (cholestatic liver injury driving kidney

damage) is also documented in AAS users in case literature.

____________________________________________________________

16 THE COMPLETE SIDE EFFECT PROFILE BY SYSTEM

CARDIOVASCULAR

LVH / dilated cardiomyopathy / MI / stroke / coronary stenosis

LDL elevation / HDL suppression / hypertension / polycythaemia

endothelial dysfunction / accelerated atherosclerosis / heart failure

NEUROLOGICAL AND PSYCHIATRIC

aggression / insomnia / acute psychosis / delirium / violent behaviour

mood instability / depression post-cycle / neurotoxicity (cell death in vitro)

Wernicke's encephalopathy (one case) / homicide (documented case reports)

ANDROGENIC

accelerated male pattern baldness / severe acne / body hair growth

prostate hypertrophy / virilisation in women (irreversible changes possible)

HORMONAL / ENDOCRINE

HPTA suppression / LH and FSH crash / endogenous testosterone to zero

progestogenic effects / elevated prolactin / possible gynecomastia

insulin resistance changes / thyroid hormone alteration

HEPATIC

elevated liver enzymes / cholestatic injury / hepatitis / peliosis hepatis

bile acid nephropathy (secondary renal involvement)

RENAL

nephropathy documented in case reports / bile acid nephropathy pathway

elevated creatinine / secondary to cardiovascular and hepatic effects

INJECTION SITE

pain / abscess / tren cough (bronchospasm post-injection) / oil embolism risk

GENERAL

night sweats / decreased appetite in some users / increased appetite in others

dark urine (from elevated hepatic and renal markers)

____________________________________________________________

17 DETECTION TIMES BY ESTER

WADA-accredited laboratory detection via LC-MS/MS urinary metabolite analysis.

Detection is of trenbolone metabolites (primarily 17alpha-trenbolone

and epitrenbolone), not the parent compound or ester.

Trenbolone acetate approximately 4-5 months post last injection

Trenbolone enanthate approximately 5-6 months post last injection

Trenbolone hexahydrobenzyl approximately 4-5 months post last injection

Trenbolone base shorter, but metabolites persist for months

These detection windows are from anti-doping laboratory data and are

substantially longer than the pharmacological activity window of the drug.

A user may have no active compound in circulation but still test positive

for months after the last injection.

____________________________________________________________

18 VERDICT RISK SUMMARY

____________________________________________________________

WHAT TRENBOLONE IS PHARMACOLOGICALLY

The most potent androgen receptor agonist in practical use. 3x testosterone

AR binding affinity confirmed in peer-reviewed binding assays. Simultaneous

anabolic, anti-catabolic, and IGF-1 amplifying mechanisms. No aromatization.

No 5AR-mediated potentiation. Unique nutrient partitioning effect.

The pharmacology is not in dispute. The compound works.

____________________________________________________________

WHAT THE EVIDENCE SAYS ABOUT RISK

Not approved for human use anywhere in the world (2024).

All available human safety data comes from case reports and user surveys,

not clinical trials. No RCT in humans for any trenbolone ester exists.

The 2025 structured review of 23 published case reports found:

cardiovascular complications in multiple cases including MI, stroke, LVH,

heart failure, and cardiomyopathy

hepatic complications in multiple cases

extreme psychiatric adverse events including psychosis and homicide

The neurotoxicity finding (Zelleroth et al. 2019): AR-mediated cell death

in brain cell cultures is documented. Long-term consequences in humans

are unknown because no long-term controlled human data exists.

____________________________________________________________

ESTER RISK HIERARCHY

From a harm reduction standpoint, faster clearance on adverse event:

base (fastest) > acetate > hexahydrobenzylcarbonate > enanthate (slowest)

Acetate is the preferred ester if harm reduction is a priority.

Enanthate is the most common due to injection convenience.

Parabolan is pharmacologically identical to other esters once cleaved.

____________________________________________________________